IMV ROCE
What is the ROCE of IMV?
The ROCE of IMV, Inc. is 0.00%
What is the definition of ROCE?
Return on capital employed (ROCE) is a financial ratio that measures a company’s profitability and the efficiency with which its capital is used.
= EBIT / (assets - current liabilities)
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE of companies in the Health Care sector on TSX compared to IMV
What does IMV do?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Companies with roce similar to IMV
- Omega Alpha Spac has ROCE of -0.01%
- The Gap has ROCE of -0.01%
- Elemental Royalties Ltd has ROCE of -0.01%
- Auburn National Bancorp has ROCE of -0.01%
- Galaxy Digital has ROCE of -0.01%
- The Gap has ROCE of -0.01%
- IMV has ROCE of 0.00%
- Tejon Ranch Co has ROCE of 0.01%
- Glen Burnie Bancorp has ROCE of 0.02%
- MSP Steel & Power has ROCE of 0.02%
- TTL Beteiligungs- und Grundbesitz-AG has ROCE of 0.03%
- First Foundation Inc has ROCE of 0.03%
- FirstMark Horizon Acquisition has ROCE of 0.03%